Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In October 2009, the US FDA approved Cervarix, a bivalent vaccine containing the oncogenic HPV types 16 and 18, for the prevention of cervical cancer and precancerous lesions in females ages 10 years through 25 years.

Updates on Adult Immunizations